Benign Prostatic Hyperplasia Prostate Treatment Market size was over USD 7.86 billion in 2024 and is likely to cross USD 16.09 billion by the end of 2037, growing at more than 5.8% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of benign prostatic hyperplasia prostate treatment is estimated at USD 8.22 billion. The growth of the market can primarily be ascribed to the growing rate of BPH surgical treatment since it can cost one’s life. Moreover, it is a disorder that is generally observed in men around the world, it is anticipated to increase the market’s growth. For instance, nearly 200,000 prostatectomy procedures are carried every year for benign diseases in the United States.
Global benign prostatic hyperplasia (BPH) prostate treatment market trends such as, the higher prevalence of benign prostatic hyperplasia (BPH) and rising awareness of the disease are estimated to hike the growth of the market over the forecast period. Moreover, benign prostatic hyperplasia has been accepted as an increasing health problem among aged men, and it is predicted to increase the market’s growth in the upcoming years. For instance, benign prostatic hyperplasia becomes more prevalent in men after the age of 40 with a prevalence rate of approximately 10% to 65% across the globe.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
5.8% |
|
Base Year Market Size (2024) |
USD 7.86 billion |
|
Forecast Year Market Size (2037) |
USD 16.09 billion |
|
Regional Scope |
|
The global benign prostatic hyperplasia (BPH) prostate treatment market is segmented and analyzed for demand and supply by treatment type into drug, and surgical treatment. Out of these, the drug treatment segment is projected to witness noteworthy growth over the forecast period. The growth of the drug treatment segment is attributed to the rising consumption of drugs across the world. There are more than 20,000 prescription drugs approved in the United States for marketing. Also, about 70% of U.S. adults take prescription drugs. Also, the increment in sales of medicines from pharmacies is considered to be another growth factor for the segment. For instance, the sales of pharmacies and drug stores were projected to be around USD 300 billion in the USA in 2020.
Moreover, the global benign prostatic hyperplasia (BPH) prostate treatment market is further segmented by therapeutic class into BPH devices and BPH drugs. Out of these, the BPH drugs segment is predicted to hold the largest share over the forecast period. This can be attributed to the increased awareness related to the use of alpha blocker for relaxing the bladder neck, which helps the urine to flow in much easier manner. Benign prostatic hyperplasia treatment is the most general treatment for the men suffering with mild to moderate benign prostatic hyperplasia (BPH) prostate symptoms, and it is projected to surge the segment’s growth in the market.
.Our in-depth analysis of the global benign prostatic hyperplasia (BPH) prostate treatment market includes the following segments:
|
By Treatment Type |
|
|
By Therapeutic Class |
|
|
By Distribution Channel |
|
North America Market Forecast
The North America market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2037. The growth of market can be ascribed to the rising geriatric population, an increasing unhealthy lifestyle, and a higher prevalence of benign prostatic hyperplasia. As per the data released by the World Bank, it was represented that in 2021, the geriatric population in the USA reached 56,545,938. Furthermore, the presence of major key players, rapidly growing healthcare infrastructure of the region, coupled with the surge in novel drug delivery systems are further projected to influence the growth of the market positively over the forecast period.
Asia Pacific Market Forecast
On the other hand, the Asia Pacific region is expected to witness the fastest growth in the upcoming years, backed by the surging urological disorders cases, rising investment in the research and development for better medical facilities, and increasing demand for the benign prostatic hyperplasia (BPH) prostate treatment in the region. Furthermore, the growing population is further projected to surge the market’s growth in the region.
Teleflex Incorporated announced the results of research studies regarding the efficacy and safety of UroLift systems. The system is developed for men diagnosed with benign prostatic hyperplasia (BPH) and median lobe obstruction.
Veru Inc. announced that it has received approval by the United States Food and Drug Administration (FDA) for its finasteride and tadalafil capsules, known as ENTADFI, which is used to treat urinary tract symptoms caused as a result of an enlarged prostate, commonly known as BPH.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?